AGN1 LOEP SV Kit Receives an Investigational Device Exemption (IDE) from the U.S. FDA
AgNovos Healthcare, a developer of medical technology products leveraging regenerative medicine to treat the local effects of bone disease, announced today that its newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) kit has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration. The IDE for the AGN1 LOEP SV kit will enable the study of the investigational device’s ability to reduce pain and support mobility in patients with vertebral compression fractures.